RECURRENT GLIOBLASTOMA

This study is testing a new combination treatment for glioblastoma, an aggressive brain cancer that has returned after initial therapy. It combines two immunotherapy drugs (tocilizumab and atezolizumab) with a precise form of radiation. The goal is to see if this three-part appro…

This early-stage study aimed to test the safety of a personalized immune therapy for people with recurrent glioblastoma, an aggressive brain cancer. Researchers planned to collect patients' own immune cells, modify them to target cancer stem cells, and reinfuse them. The main goa…

This early-phase trial is testing a new type of personalized immunotherapy for patients with malignant brain tumors (gliomas) that have returned or stopped responding to standard treatments. Doctors collect a patient's own immune cells (T-cells), genetically modify them in a lab …

This is an early-stage safety study for a new type of CAR T-cell therapy designed for adults with a specific type of recurrent brain cancer called glioblastoma. The main goals are to find the safest dose and understand the side effects. Doctors will collect a patient's own immune…

This study is testing a new approach for treating glioblastoma when it returns after initial treatment. It compares a new method—using an implanted ultrasound device to temporarily open the brain's protective barrier so more chemotherapy can reach the tumor—against standard chemo…

This early-stage trial is testing whether adding a drug called mycophenolate mofetil (MMF) to standard glioblastoma treatment is safe and might make the cancer more sensitive to chemotherapy. MMF is an immunosuppressant commonly used to prevent organ rejection after transplants. …

This early study is testing whether daily progesterone injections can help control tumor growth in adults whose aggressive brain cancer (glioblastoma) has returned. Researchers want to find the safest dose and see if the treatment can stabilize the disease. The study involves a v…

This early-stage study is testing a new drug called ST101 in patients with advanced solid tumors that cannot be surgically removed and have spread. The trial aims to find a safe and effective dose for cancers including glioblastoma, melanoma, breast cancer, and prostate cancer in…

This early-stage study is testing personalized mRNA vaccines for adults with recurrent glioblastoma, an aggressive brain cancer. Researchers will create vaccines using genetic material from each patient's own tumor tissue, combined with a standard mRNA component. The main goals a…

This study is testing whether combining a pill called niraparib with a wearable device that delivers Tumor-Treating Fields (TTFields) can help control recurrent glioblastoma, a very aggressive brain cancer. The goal is to see if the device makes the tumor cells more vulnerable to…

This early-stage study is testing the safety of a new two-part treatment for aggressive brain tumors that have returned after standard therapy. Doctors place genetically modified stem cells directly into the brain during surgery, hoping these cells will make the tumor more sensit…

This early-stage study is testing a new two-drug combination (BGB-290 and temozolomide) for adolescents and young adults with specific types of brain tumors that have returned or are newly diagnosed. The main goal is to find the safest dose and understand the side effects. Resear…

This study is testing whether a special type of MRI scan can predict how well patients with recurrent glioblastoma (a type of brain cancer) will respond to the drug bevacizumab. Researchers are measuring changes in blood flow within the tumor two weeks after starting treatment to…

This early study aims to see if two new oral drugs, defactinib or VS-6766, can reach brain tumors in patients with glioblastoma. Researchers will give a single dose to 14 patients before their scheduled tumor removal surgery. The main goals are to measure how much drug gets into …